Journal
BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
Volume 25, Issue 2, Pages 224-234Publisher
KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
DOI: 10.1007/s12257-019-0047-0
Keywords
polyamidoamine (PAMAM) dendrimer; oxaliplatin; low charge-associated toxicity; drug delivery systems; cancer therapy
Categories
Ask authors/readers for more resources
Polyamidoamine (PAMAM) dendrimer is emerging as an effective nanocarrier for delivering anticancer drugs. Still, unmodified PAMAM dendrimer is hardly used in vivo because of unsatisfied drug release, high tendency of interfering with cellular membranes, and rapid clearance by reticuloendothelial system. In this study, low generation polyamidoamine (PAMAM) dendrimer G3.0 is developed and surface modified with methoxypolyethylene glycol (PAMAM G3.0-mPEG) to overcome its limitations. Specifically, PAMAM G3.0 conjugated with mPEG at different ratios are investigated to effectively eliminate its charge-associated toxicity, in which PAMAM G3.0-mPEG-8 is chosen for oxaliplatin (OX) loading. Results reveal that OX-loaded PAMAM G3.0-mPEG-8 has desirable size, good entrapment efficiency, and sustained release with minimum drug leakage. In addition, Resazurin assay indicates that the toxicity of loaded OX is reduced as compared to free drug but still maintain substantially anticancer activity on HeLa cells, suggesting the potential application of PAMAM G3.0-mPEG-8 for OX delivery in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available